Shots:
The US FDA has granted IND clearance to SNUG01 for ALS
SNUG01 will be evaluated in a P-I/IIa dose-escalation & expansion trial to assess its safety, tolerability, & preliminary efficacy in ALS adults; SineuGene to partner with academics & institutions to lead clinical development of SNUG01
SNUG01, a TRIM72-targeted gene therapy, counteracts ALS through…
